Free Access
Med Sci (Paris)
Volume 19, Number 10, Octobre 2003
Page(s) 910 - 919
Section M/S Revues
Published online 15 October 2003
  1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J Clin 2003; 53: 5–26. [Google Scholar]
  2. Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer ? Urology 2002; 60: 115–9. [Google Scholar]
  3. Labrie F, Bélanger A, Cusan L, et al. Antifertility effects of LHRH agonists in the male. J Androl 1980; 1: 209–28. [Google Scholar]
  4. Huggins C, Hodges CV. Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–307. [Google Scholar]
  5. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295–300. [Google Scholar]
  6. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of radiation therapy oncology group protocol 85–31. J Clin Oncol 1997; 15: 1013–21. [Google Scholar]
  7. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781–8. [Google Scholar]
  8. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83–91. [Google Scholar]
  9. Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998; 159: 2030–4. [Google Scholar]
  10. Hanks GE, Lu J, Machtay M, et al. RTOG Protocol 92-02: A Phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. In: Program and abstracts of the American Society of Clinical Oncology 36th Annual Meeting May, 20-23: New Orleans. Americain Society of Clinical Oncology, 2000: 1284 (abstract). [Google Scholar]
  11. Labrie C, Bélanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 1988; 123: 1412–7. [Google Scholar]
  12. Labrie F. Intracrinology. Mol Cell Endocrinol 1991; 78: C113–C8. [Google Scholar]
  13. Labrie F, Dupont A, Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In: de Vita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: J.B. Lippincott, 1985: 193- 217. [Google Scholar]
  14. Labrie F, Luu-The V, Lin SX, Simard J, Labrie C. Role of 17beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol Metab 2000; 11: 421–7. [Google Scholar]
  15. Stewart PM, Sheppard MC. Novel aspects of hormone action: intracellular ligand supply and its control by a series of tissue-specific enzymes. Mol Cell Endocrinol 1992; 83: C13–C8. [Google Scholar]
  16. Labrie F, Dupont A, Bélanger A, et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982; 5: 267–75. [Google Scholar]
  17. Labrie F, Bélanger A, Cusan L, et al. History of LHRH agonists and combination therapy in prostate cancer. Endocrine-Related Cancer 1996; 3: 243–78. [Google Scholar]
  18. Labrie F. Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 1993; 72: 3816–27. [Google Scholar]
  19. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–24. [Google Scholar]
  20. Janknegt RA, Abbou CC, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149: 77–83. [Google Scholar]
  21. Dijkman GA, Janknegt RA, Dereijke TM, Debruyne FMJ. Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization. J Urol 1997; 158: 160–3. [Google Scholar]
  22. Caubet JF, Tosteson TD, Dong EW, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49: 71–8. [Google Scholar]
  23. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. Eur Urol 1998; 33: 144–51. [Google Scholar]
  24. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgenblockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prost Dis 1999; 2: 4–8. [Google Scholar]
  25. Labrie F, Dupont A, Suburu R, et al. Serum prostate specific antigen (PSA) as prescreening test for prostate cancer. J Urol 1992; 147: 846–52. [Google Scholar]
  26. Labrie F, Candas B, Cusan L, et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996; 47: 212–7. [Google Scholar]
  27. Candas B, Cusan L, Gomez JL, et al. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate 2000; 45: 19–35. [Google Scholar]
  28. Labrie F. Screening and hormonal therapy of localized prostate cancer show major benefits on survival. Cancer J Sci Am 2000; 6: S182–7. [Google Scholar]
  29. Labrie F. Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. Prostate 2000; 43: 215–22. [Google Scholar]
  30. American Urological Association. Board of directors report: early detection of prostate. New York : American Urological Association, 2001. [Google Scholar]
  31. Makinen T, Tammela TL, Hakama M, et al. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng/ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. J Urol 2001; 166: 1339–42. [Google Scholar]
  32. Schröder FH, van der Maas P, Beemsterboer P, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 1998; 90: 1817–23. [Google Scholar]
  33. Lodding P, Aus G, Bergdahl S, et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml prostate specific antigen. J Urol 1998; 159: 899–903. [Google Scholar]
  34. Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination. Urology 2001; 57: 83–90. [Google Scholar]
  35. Bartsch G, Horninger W, Klocker H, et al. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria. AUA Annual Meeting. J Urol 2000; 163: 88 (abstract 387). [Google Scholar]
  36. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 2003; 169: 1720–3. [Google Scholar]
  37. Labrie F, Cusan L, Gomez JL, Diamond P, Bélanger A. Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol Urol 1997; 1: 253–61. [Google Scholar]
  38. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 247–52. [Google Scholar]
  39. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant Tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88: 1543–9. [Google Scholar]
  40. Neri RO, Monahan MD, Meyer JG, Afonso BA, Tabachnick IA. Biological studies on an antiandrogen (SH 714). Eur J Pharmacol 1967; 1: 438–44. [Google Scholar]
  41. Labrie F, Belanger A, Dupont A, Emond J, Lacoursiere Y, Monfette G. Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet 1984; 2: 1090. [Google Scholar]
  42. Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 1, 2 and 3 17beta-hydroxysteroid dehydrogenase activities: oxidation-reduction and inhibition. J Steroid Biochem Mol Biol 1995; 55: 581–7. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.